# Peptide Mechanisms of Action - Clinical Comparison Matrix

**For Healthcare Practitioners**  
**Last Updated:** November 29, 2025

---

## Overview

This matrix compares peptides by their primary molecular mechanisms, helping practitioners select the most appropriate peptide based on the underlying pathophysiology of the patient's condition.

---

## Tissue Repair & Regeneration Peptides

| Peptide | Primary Mechanism | Molecular Targets | Tissue Specificity | Onset of Action | Evidence Quality |
|---------|-------------------|-------------------|-------------------|-----------------|------------------|
| **BPC-157** | Angiogenesis promotion, VEGFR2 activation, nitric oxide modulation | VEGFR2, eNOS, FAK, growth factor pathways | Broad (GI, tendon, ligament, muscle, bone, vascular) | 3-7 days | Animal (extensive), Human (case series) |
| **TB-500 (Thymosin β4)** | Actin sequestration, cell migration, anti-inflammatory | G-actin, integrin signaling, NF-κB inhibition | Broad (cardiac, skeletal muscle, tendon, wound) | 5-10 days | Animal + Human trials (cardiac) |
| **GHK-Cu** | Collagen/elastin synthesis, metalloproteinase modulation, antioxidant | TGF-β, MMP inhibition, copper-dependent enzymes | Skin, wound healing, hair follicles | 2-4 weeks | Animal + Human (dermatology) |
| **MGF (Mechano Growth Factor)** | Satellite cell activation, muscle hypertrophy signaling | IGF-1 receptor (splice variant), mTOR pathway | Skeletal muscle (highly specific) | Post-exercise (hours) | Mechanism + observational |

**Clinical Selection Guide:**
- **Acute injury:** BPC-157 (fastest angiogenesis)
- **Chronic tendinopathy:** TB-500 (anti-fibrotic effects)
- **Skin/aesthetic:** GHK-Cu (collagen remodeling)
- **Muscle hypertrophy:** MGF (satellite cell activation)

---

## Growth Hormone Axis Peptides

| Peptide | Primary Mechanism | Receptor Target | GH Pulse Pattern | Half-Life | Metabolic Effects |
|---------|-------------------|-----------------|------------------|-----------|-------------------|
| **CJC-1295 (DAC)** | GHRH analog with albumin binding (extended release) | GHRH receptor | Sustained elevation (days) | ~6-8 days | IGF-1 ↑, lipolysis ↑, lean mass ↑ |
| **CJC-1295 (No DAC)** | GHRH analog, short-acting | GHRH receptor | Pulsatile (mimics natural) | ~30 minutes | IGF-1 ↑, preserves pulsatility |
| **Ipamorelin** | Ghrelin mimetic, selective GH secretagogue | Ghrelin receptor (GHS-R1a) | Pulsatile, no cortisol/prolactin spike | ~2 hours | GH ↑, appetite ↑ (mild), lean mass ↑ |
| **Sermorelin** | GHRH analog (1-29 fragment) | GHRH receptor | Pulsatile (mimics natural) | ~10-20 minutes | IGF-1 ↑, preserves feedback loops |
| **Tesamorelin** | GHRH analog (FDA-approved for HIV lipodystrophy) | GHRH receptor | Pulsatile, visceral fat-specific | ~26-38 minutes | Visceral fat ↓↓, IGF-1 ↑ |
| **GHRP-2** | Ghrelin mimetic, potent GH secretagogue | Ghrelin receptor | Strong pulsatile, cortisol/prolactin ↑ | ~20 minutes | GH ↑↑, appetite ↑↑ |
| **GHRP-6** | Ghrelin mimetic, appetite stimulation | Ghrelin receptor | Pulsatile, cortisol/prolactin ↑ | ~20 minutes | GH ↑, appetite ↑↑↑ |
| **Ibutamoren (MK-677)** | Oral ghrelin mimetic | Ghrelin receptor | Sustained GH/IGF-1 elevation | ~24 hours | GH ↑, appetite ↑↑, sleep quality ↑ |

**Clinical Selection Guide:**
- **Preserve pulsatility:** CJC-1295 (no DAC) + Ipamorelin
- **Convenience (long-acting):** CJC-1295 (DAC)
- **Visceral fat:** Tesamorelin (FDA-approved indication)
- **Appetite stimulation needed:** GHRP-6, Ibutamoren
- **Avoid cortisol/prolactin:** Ipamorelin, Sermorelin

---

## Weight Loss & Metabolic Peptides

| Peptide | Primary Mechanism | Receptor Target | Weight Loss Magnitude | Metabolic Effects | GI Tolerability |
|---------|-------------------|-----------------|----------------------|-------------------|-----------------|
| **Semaglutide** | GLP-1 receptor agonist | GLP-1R | 15-17% at 68 weeks | Insulin ↑, glucagon ↓, gastric emptying ↓ | Moderate (nausea 44%) |
| **Tirzepatide** | Dual GIP/GLP-1 receptor agonist | GIP-R + GLP-1R | 20-22% at 72 weeks | Enhanced insulin, lipolysis ↑, satiety ↑↑ | Moderate-high (nausea 30-40%) |
| **Retatrutide** | Triple GIP/GLP-1/glucagon agonist | GIP-R + GLP-1R + GCGR | 24% at 48 weeks (Phase 3) | Metabolic rate ↑, lipolysis ↑↑, satiety ↑↑ | High (investigational) |
| **Cagrilintide** | Amylin analog | Amylin receptor | 10-15% (combo with semaglutide: 25%) | Gastric emptying ↓↓, satiety ↑, glucagon ↓ | Moderate |
| **AOD-9604** | hGH fragment (176-191), lipolytic | β3-adrenergic (indirect) | 5-8% (targeted fat loss) | Lipolysis ↑, no IGF-1 effects | Excellent |
| **5-Amino-1MQ** | NNMT inhibitor (increases NAD+) | NNMT enzyme | 3-5% (metabolic optimization) | NAD+ ↑, mitochondrial function ↑ | Excellent |

**Clinical Selection Guide:**
- **First-line obesity:** Semaglutide (FDA-approved, established safety)
- **Maximum weight loss:** Tirzepatide (superior efficacy)
- **Investigational/cutting-edge:** Retatrutide (Phase 3 trials)
- **Combination therapy:** Semaglutide + Cagrilintide (synergistic)
- **Targeted fat loss (no systemic):** AOD-9604
- **Metabolic optimization:** 5-Amino-1MQ

---

## Cognitive Enhancement & Neuroprotection Peptides

| Peptide | Primary Mechanism | Molecular Targets | Cognitive Domain | Onset | Evidence |
|---------|-------------------|-------------------|------------------|-------|----------|
| **Semax** | BDNF upregulation, neurotrophin signaling | TrkB receptor, BDNF/NGF pathways | Focus, memory, processing speed | 30-60 minutes | RCTs (Russia), mechanism |
| **Selank** | Anxiolytic, GABA modulation, enkephalin metabolism | GABA-A, enkephalinase inhibition | Anxiety ↓, stress resilience ↑ | 30-60 minutes | RCTs (Russia), mechanism |
| **Dihexa** | NMDA potentiation, HGF/c-Met pathway | HGF receptor (c-Met), NMDA | Memory consolidation, neuroplasticity | 1-2 weeks | Animal (potent), human (limited) |
| **Cerebrolysin** | Neurotrophic peptide mixture (porcine brain-derived) | Multiple neurotrophic pathways | Neuroprotection, stroke recovery | Days to weeks | RCTs (stroke, dementia) |
| **NAD+** | Mitochondrial cofactor, sirtuin activation | Sirtuins (SIRT1-7), PARP, mitochondria | Energy, neuroprotection, anti-aging | Hours (acute), weeks (chronic) | Mechanism + observational |
| **Pinealon** | Pineal gland peptide, circadian regulation | Circadian clock genes | Sleep quality, melatonin regulation | 1-2 weeks | Animal + observational |

**Clinical Selection Guide:**
- **ADHD-like symptoms:** Semax (focus + processing speed)
- **Anxiety + cognitive:** Selank (anxiolytic without sedation)
- **Memory impairment:** Dihexa (potent neuroplasticity, use cautiously)
- **Stroke/TBI recovery:** Cerebrolysin (established in neurology)
- **Brain fog/fatigue:** NAD+ (mitochondrial support)
- **Sleep optimization:** Pinealon (circadian regulation)

---

## Immune Modulation & Anti-Inflammatory Peptides

| Peptide | Primary Mechanism | Immune Effect | Clinical Applications | Onset | Evidence |
|---------|-------------------|---------------|----------------------|-------|----------|
| **Thymosin Alpha-1** | T-cell maturation, Th1 response upregulation | Immune stimulation | Chronic infections, hepatitis, cancer adjunct | 2-4 weeks | RCTs (hepatitis, sepsis) |
| **LL-37** | Antimicrobial peptide, immune modulation | Direct pathogen killing, immune signaling | Biofilm infections, wound healing | Days to weeks | Mechanism + case series |
| **KPV** | Anti-inflammatory tripeptide (α-MSH derivative) | MSH receptor, NF-κB inhibition | IBD, inflammatory conditions | 1-2 weeks | Animal + observational |
| **BPC-157** | Anti-inflammatory, tissue repair | NF-κB inhibition, angiogenesis | GI inflammation, systemic inflammation | 3-7 days | Animal (extensive) |

**Clinical Selection Guide:**
- **Immune deficiency:** Thymosin Alpha-1 (T-cell support)
- **Chronic infections:** LL-37 + Thymosin Alpha-1 (synergistic)
- **Inflammatory bowel disease:** KPV + BPC-157 (anti-inflammatory + repair)
- **Wound infections:** LL-37 (antimicrobial) + BPC-157 (healing)

---

## Anti-Aging & Longevity Peptides

| Peptide | Primary Mechanism | Molecular Targets | Aging Hallmarks Addressed | Evidence |
|---------|-------------------|-------------------|---------------------------|----------|
| **Epithalon** | Telomerase activation, pineal function | Telomerase, melatonin regulation | Telomere attrition, circadian dysfunction | Animal + observational |
| **GHK-Cu** | Collagen synthesis, gene expression modulation | 4,000+ genes, TGF-β, MMPs | Cellular senescence, extracellular matrix degradation | Animal + human (dermatology) |
| **Humanin** | Mitochondrial-derived peptide, neuroprotection | FPRL1/2 receptors, apoptosis inhibition | Mitochondrial dysfunction, proteostasis | Mechanism + observational |
| **MOTSc** | Mitochondrial-derived peptide, metabolic regulation | AMPK activation, insulin sensitivity | Metabolic dysfunction, mitochondrial decline | Mechanism + observational |
| **SS-31 (Elamipretide)** | Mitochondrial membrane stabilization | Cardiolipin binding, ROS reduction | Mitochondrial dysfunction, oxidative stress | Clinical trials (heart failure, mitochondrial disease) |
| **NAD+** | Mitochondrial cofactor, sirtuin activation | Sirtuins, PARP, mitochondrial enzymes | NAD+ decline, mitochondrial dysfunction | Mechanism + observational |

**Clinical Selection Guide:**
- **Telomere/epigenetic aging:** Epithalon (telomerase activation)
- **Skin aging:** GHK-Cu (collagen + gene expression)
- **Mitochondrial dysfunction:** SS-31 (clinical trials) or NAD+ (broader availability)
- **Metabolic aging:** MOTSc (insulin sensitivity)
- **Neuroprotection:** Humanin (anti-apoptotic)

---

## Mechanism-Based Peptide Selection Algorithm

### Step 1: Identify Primary Pathophysiology

**Tissue Damage/Injury:**
- Angiogenesis needed → BPC-157
- Anti-fibrotic needed → TB-500
- Collagen remodeling → GHK-Cu

**Metabolic Dysfunction:**
- GH deficiency → CJC-1295 + Ipamorelin
- Obesity → Semaglutide or Tirzepatide
- Insulin resistance → MOTSc or NAD+

**Neurological:**
- Cognitive decline → Semax, Dihexa, or Cerebrolysin
- Anxiety → Selank
- Neuroprotection → NAD+, Humanin

**Immune:**
- Immune deficiency → Thymosin Alpha-1
- Chronic infection → LL-37 + Thymosin Alpha-1
- Inflammation → KPV + BPC-157

**Aging:**
- Cellular senescence → Epithalon, GHK-Cu
- Mitochondrial → SS-31, NAD+, MOTSc
- Multi-system → Combination approach

### Step 2: Consider Mechanism Overlap for Stacking

**Synergistic Mechanisms:**
- BPC-157 + TB-500 (angiogenesis + anti-fibrotic)
- Semax + NAD+ (neurotrophin + mitochondrial)
- GHK-Cu + Epithalon (collagen + telomerase)

**Avoid Redundant Mechanisms:**
- Multiple GLP-1 agonists (Semaglutide + Tirzepatide)
- Excessive GH secretagogues (>3 simultaneously)

### Step 3: Match Mechanism to Patient Factors

**Age Considerations:**
- <40 years: Focus on performance/optimization
- 40-60 years: Metabolic + early aging interventions
- >60 years: Longevity + neuroprotection priority

**Comorbidities:**
- Diabetes: GLP-1 agonists, avoid excessive GH
- Cardiovascular: Tesamorelin (visceral fat), SS-31 (mitochondrial)
- Autoimmune: Avoid immune stimulators (TA1, LL-37)

---

## Receptor Specificity & Cross-Reactivity

### High Specificity (Minimal Off-Target Effects)

- **Ipamorelin:** Ghrelin receptor (no cortisol/prolactin)
- **Tesamorelin:** GHRH receptor (visceral fat-specific effects)
- **KPV:** MSH receptor (anti-inflammatory specific)

### Moderate Specificity

- **BPC-157:** Multiple pathways (VEGFR2, eNOS, FAK)
- **GHK-Cu:** Broad gene expression effects (4,000+ genes)
- **Semax:** Neurotrophin pathways (BDNF, NGF)

### Broad/Multi-Target

- **Thymosin Alpha-1:** Multiple immune pathways
- **Cerebrolysin:** Mixture of neurotrophic peptides
- **NAD+:** Universal cofactor (sirtuins, PARP, mitochondria)

**Clinical Implication:** High specificity peptides are easier to predict and monitor; broad-target peptides may have more comprehensive effects but require careful monitoring.

---

## Pharmacokinetic Considerations

### Rapid Onset (<1 hour)

- Semax, Selank (intranasal)
- Ipamorelin (GH pulse)
- GHRP-2, GHRP-6 (GH pulse)

**Clinical Use:** Acute symptom management, pre-workout, cognitive demands

### Intermediate Onset (Hours to Days)

- BPC-157 (angiogenesis initiation)
- NAD+ (mitochondrial effects)
- LL-37 (antimicrobial)

**Clinical Use:** Subacute conditions, injury recovery

### Delayed Onset (Weeks)

- GHK-Cu (collagen remodeling)
- Epithalon (telomerase effects)
- Dihexa (neuroplasticity)

**Clinical Use:** Chronic conditions, anti-aging, structural changes

### Cumulative Effect (Months)

- Growth hormone secretagogues (body composition)
- GLP-1 agonists (weight loss)
- Longevity peptides (aging biomarkers)

**Clinical Use:** Long-term optimization, metabolic conditions

---

## Evidence-Based Mechanism Validation

### Well-Established Mechanisms (Human RCTs)

- Semaglutide, Tirzepatide (GLP-1/GIP pathways)
- Tesamorelin (GHRH pathway)
- Thymosin Alpha-1 (immune modulation)
- Cerebrolysin (neurotrophic effects)

### Mechanism Supported (Animal + Human Observational)

- BPC-157 (angiogenesis, tissue repair)
- TB-500 (actin sequestration, migration)
- GHK-Cu (collagen synthesis, gene expression)
- Semax, Selank (neurotrophin, anxiolytic)

### Theoretical Mechanism (Limited Human Data)

- Dihexa (HGF/c-Met, NMDA potentiation)
- Humanin, MOTSc (mitochondrial-derived peptides)
- Epithalon (telomerase activation)
- 5-Amino-1MQ (NNMT inhibition)

**Clinical Implication:** Prioritize well-established mechanisms for first-line therapy; use theoretical mechanisms for refractory cases or optimization with informed consent.

---

## Practical Application: Mechanism-Based Case Examples

### Case 1: 45-year-old male, chronic Achilles tendinopathy

**Pathophysiology:** Failed healing, fibrosis, poor vascularization

**Mechanism Selection:**
- Primary: BPC-157 (angiogenesis, 500 mcg SC daily)
- Secondary: TB-500 (anti-fibrotic, 5 mg SC 2x/week)

**Rationale:** Synergistic mechanisms address both vascular and fibrotic components

---

### Case 2: 58-year-old female, obesity + metabolic syndrome

**Pathophysiology:** Insulin resistance, visceral adiposity, inflammation

**Mechanism Selection:**
- Primary: Tirzepatide (dual GIP/GLP-1, titrate to 10-15 mg weekly)
- Optional: BPC-157 (GI protection, 250 mcg SC daily)

**Rationale:** Dual agonist superior efficacy; BPC-157 mitigates GI side effects

---

### Case 3: 62-year-old male, cognitive decline + fatigue

**Pathophysiology:** Mitochondrial dysfunction, neuroinflammation, NAD+ decline

**Mechanism Selection:**
- Primary: NAD+ (mitochondrial support, 250 mg SC 3x/week)
- Secondary: Semax (neurotrophin upregulation, 600 mcg IN 2x/day)

**Rationale:** Complementary mechanisms (mitochondrial + neurotrophin)

---

## References

**Key Mechanistic Studies:**
- BPC-157 angiogenesis: Multiple animal models (2010-2024)
- GLP-1 mechanisms: STEP trials (NEJM 2021)
- GIP/GLP-1 dual agonism: SURMOUNT trials (NEJM 2022)
- Growth hormone pathways: Multiple clinical trials
- Mitochondrial peptides: Emerging research (2015-2024)

---

**Clinical Use Disclaimer:**
This matrix is for healthcare practitioner reference only. Mechanisms are based on current scientific understanding and may evolve with new research. Many peptides listed are not FDA-approved for the indications described.

**Last Updated:** November 29, 2025  
**Next Review:** February 2026

---

**For Healthcare Practitioners**  
**DrsPeptides.com - Evidence-Based Peptide Protocols**
